RxSight (RXST) Amortization of Deferred Charges (2020 - 2025)
RxSight (RXST) posted Amortization of Deferred Charges of -$9000.0 for Q2 2025, down 200.0% on a QoQ basis from $9000.0 in Q1 2025, and down 212.5% year-over-year from $8000.0 in Q2 2024.
RxSight (RXST) Amortization of Deferred Charges (2020 - 2025) Analysis & Trends
RxSight's Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at -$9000.0 for Q2 2025.
- Quarterly Amortization of Deferred Charges fell 212.5% year-over-year to -$9000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$9000.0 (up 43.75% YoY) and the FY2023 annual result came in at $287000.0, down 48.01% from the prior year.
- Amortization of Deferred Charges was -$9000.0 for Q2 2025 at RxSight, down from $9000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $457000.0 in Q4 2022 and bottomed at -$99000.0 in Q2 2021.
- A 5-year average of $47333.3 and a median of $17000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges jumped 7716.67% — and 2025, when it sank 212.5%.
- RxSight's Amortization of Deferred Charges stood at -$6000.0 in 2021, then soared by 7716.67% to $457000.0 in 2022, then slumped by 66.08% to $155000.0 in 2023, then sank by 126.45% to -$41000.0 in 2024, then surged by 78.05% to -$9000.0 in 2025.
- Business Quant data shows RXST's Amortization of Deferred Charges at -$9000.0 in Q2 2025, $9000.0 in Q1 2025, and -$41000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | RxSight | 221.81 Mn | -196.39 Mn | 23.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -9,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Dec 31, 2024 | -41,000.00 |
| Dec 31, 2024 | -41,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | 25,000.00 |
| Mar 31, 2024 | 25,000.00 |
| Dec 31, 2023 | 155,000.00 |
| Dec 31, 2023 | 155,000.00 |
| Sep 30, 2023 | 47,000.00 |
| Sep 30, 2023 | 47,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Mar 31, 2023 | 44,000.00 |
| Mar 31, 2023 | 44,000.00 |